Nutritional interventions targeting gut microbial balance and intestinal barrier function may support gastrointestinal health (1). Ovitage® is a novel technology that isolates a range of peptides from sheep skin. These include collagen and keratin peptides as well as peptides associated with basement membrane and follicle tissue. Peptide sequences identified in Ovitage® using proteomic analysis are known to promote tissue healing. This includes, for example, cystine rich peptides that have been shown to increase the production of collagen IV and collagen VII in epidermal tissue, both of which are structural membrane proteins involved in epithelial barrier integrity (2). The Ovitage® complex in this study also contains a kiwifruit extract shown to increase the abundance of Faecalibacterium prausnitzii, a butyrate-producing gut commensal associated with intestinal barrier function and gastrointestinal health (3). This 8-week pilot study evaluated the effects of the Ovitage® bioactive peptide complex supplementation on self-reported gastrointestinal symptoms in women. In this decentralised, open-label, single-cohort study, 29 participants commenced supplementation with a daily nutritional supplement containing 700 mg of the Ovitage® bioactive peptides complex, administered as two capsules daily. One week prior to supplementation, participants completed an online baseline questionnaire assessing gastrointestinal symptoms experienced during the preceding four weeks. Weekly follow-up questionnaires were completed throughout the intervention period. Questionnaires were developed with reference to the Gastrointestinal Symptom Rating Scale (GSSR) (4) and assessed symptom frequency and severity, lifestyle factors, gastrointestinal diagnoses, and self-reported food sensitivities and intolerances. 20 participants completed the 8-week intervention. Improvements were observed across all assessed gastrointestinal symptoms. By week 4, more than 50% of participants reported improvement in 7 of the 8 symptoms evaluated. The proportion reporting improved overall gut health increased from 21.4% at week 1 to 85.0% at week 8. Mean self-rated gut health scores increased significantly from 5.45 at baseline to 7.70 at week 8 (p < 0.005) with statistical analysis based on a student’s t test. Symptom severity scores decreased across all gastrointestinal domains, with the greatest and most consistent improvements observed for abdominal pain/discomfort and bloating. Statistical significance (p < 0.005) was observed for symptom scores comparing week 0 to week 8 for abdominal pain/discomfort, bloating, constipation and flatulence with differences of lower significance (p < 0.05) observed for diarrhoea and abdominal distention. Supplementation with Ovitage® bioactive peptide complex was associated with improvements in self-reported gastrointestinal symptoms and perceived gut health in women over an 8-week period. These preliminary findings support further investigation in larger, randomised, placebo-controlled clinical trials.